Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics

2005 Williams, 1998, The response-to-retention hypothesis of atherogenesis reinforced, Curr Opin Lipidol, 9, 471, 10.1097/00041433-199810000-00012 Levine, 1995, Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms, N Engl J Med, 332, 512, 10.1056/NEJM199502233320807 Vaughan, 2000, The evolving role of statins in the management of atherosclerosis, J Am Coll Cardiol, 35, 1, 10.1016/S0735-1097(99)00525-2 McKenney, 2005, Efficacy and safety of rosuvastatin in treatment of dyslipidemia, Am J Health Syst Pharm, 62, 1033, 10.1093/ajhp/62.10.1033 Martin, 2003, Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers, Clin Ther, 25, 2553, 10.1016/S0149-2918(03)80316-8 McTaggart, 2001, Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, Am J Cardiol, 87, 28B, 10.1016/S0002-9149(01)01454-0 Hsiang, 1999, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters, J Biol Chem, 274, 37161, 10.1074/jbc.274.52.37161 McTaggart, 2003, Comparative pharmacology of rosuvastatin, Atheroscler Suppl, 4, 9, 10.1016/S1567-5688(03)00004-7 Kim, 2003, Organic anion-transporting polypeptide (OATP) transporter family and drug disposition, Eur J Clin Invest, 33, 1, 10.1046/j.1365-2362.33.s2.5.x Schneck, 2004, The effect of gemfibrozil on the pharmacokinetics of rosuvastatin, Clin Pharmacol Ther, 75, 455, 10.1016/j.clpt.2003.12.014 Simonson, 2004, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine, Clin Pharmacol Ther, 76, 167, 10.1016/j.clpt.2004.03.010 Regazzi, 1993, Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients, Transplant Proc, 25, 2732 Shitara, 2003, Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A, J Pharmacol Exp Ther, 304, 610, 10.1124/jpet.102.041921 Tirona, 2003, Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation, J Pharmacol Exp Ther, 304, 223, 10.1124/jpet.102.043026 Tirona, 2001, Polymorphisms in OATP-C, J Biol Chem, 276, 35669, 10.1074/jbc.M103792200 Ho, 2004, Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition, J Biol Chem, 279, 7213, 10.1074/jbc.M305782200 Kim, 1999, Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity, J Pharmacol Exp Ther, 291, 1204 Singer, 1984, Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers, Proc Natl Acad Sci U S A, 81, 5556, 10.1073/pnas.81.17.5556 Tan, 1999, Lack of zonal uptake of estrone sulfate in enriched periportal and perivenous isolated rat hepatocytes, Drug Metab Dispos, 27, 336 Paulusma, 2000, Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver, Hepatology, 31, 684, 10.1002/hep.510310319 Hirano, 2005, Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin, Mol Pharmacol, 68, 800, 10.1124/mol.105.014019 Maliepaard, 2001, Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues, Cancer Res, 61, 3458 Kouzuki, 1998, Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes, J Pharmacol Exp Ther, 286, 1043 Duffy, 1983, Direct determination of the driving forces for taurocholate uptake into rat liver plasma membrane vesicles, J Clin Invest, 72, 1470, 10.1172/JCI111103 Satlin, 1997, Organic anion transporting polypeptide mediates organic anion/HCO3- exchange, J Biol Chem, 272, 26340, 10.1074/jbc.272.42.26340 Davidson, 2004, Comparative effects of lipid-lowering therapies, Prog Cardiovasc Dis, 47, 73, 10.1016/j.pcad.2004.04.007 Mwinyi, 2004, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics, Clin Pharmacol Ther, 75, 415, 10.1016/j.clpt.2003.12.016 Nishizato, 2003, Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes, Clin Pharmacol Ther, 73, 554, 10.1016/S0009-9236(03)00060-2 Niemi, 2004, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1), Pharmacogenetics, 14, 429, 10.1097/01.fpc.0000114750.08559.32 Nozawa, 2002, Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9), J Pharmacol Exp Ther, 302, 804, 10.1124/jpet.302.2.804 Tachibana-Iimori, 2004, Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors, Drug Metab Pharmacokinet, 19, 375, 10.2133/dmpk.19.375 Morimoto, 2005, OATP-C (OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients, Clin Pharmacol Ther, 77, 21, 10.1016/j.clpt.2004.11.081 Trauner, 2003, Bile salt transporters, Physiol Rev, 83, 633, 10.1152/physrev.00027.2002 Hagenbuch, 2004, The sodium bile salt cotransport family SLC10, Pflugers Arch, 447, 566, 10.1007/s00424-003-1130-z Baker, 2001, Temporal gene expression analysis of monolayer cultured rat hepatocytes, Chem Res Toxicol, 14, 1218, 10.1021/tx015518a Jigorel, 2005, Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes, Drug Metab Dispos, 33, 1418, 10.1124/dmd.105.004762 Shitara, 2003, Function of uptake transporters for taurocholate and estradiol 17β-D-glucuronide in cryopreserved human hepatocytes, Drug Metab Pharmacokinet, 18, 33, 10.2133/dmpk.18.33 Cooper, 2003, Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects, Br J Clin Pharmacol, 55, 94, 10.1046/j.1365-2125.2003.01720.x Poynter, 2005, Statins and the risk of colorectal cancer, N Engl J Med, 352, 2184, 10.1056/NEJMoa043792 Garcia, 2005, Pleiotropic effects of statins, Curr Atheroscler Rep, 7, 34, 10.1007/s11883-005-0073-6